Case Study: Leading Pharmaceutical Company achieves 43% faster enrollment (900 patients in 30 weeks) with IQVIA Biotech

Enrollment Timeline Reduced by 43%

Leading Pharmaceutical Company engaged IQVIA Biotech (IQVIA) to provide patient recruitment services for a Phase III external genital warts study that needed to enroll 900 young adults (ages 18–30). The challenge was recruiting a transient, hard-to-reach population and achieving an even male/female distribution while meeting aggressive timeline and budget constraints.

IQVIA deployed its predictive enrollment model and targeted, gender-tailored spot-market advertising with daily tracking and site-level optimization, using a performance-based approach that addressed screening and pre-randomization loss points. As a result, IQVIA completed full enrollment of 900 randomized patients by week 30—22 weeks ahead of the sponsor’s 52-week projection (a 43% reduction)—achieved a near-even 46% male/54% female split, and lowered per-response advertising costs to keep media spend below projections.